Piramal Pharma Operational Benchmarking
₹202.63+1.05%
- Market cap
- ₹26,843 crore
- P/E
- 22.5
- P/B
- 3.29
- ROE
- -4.0%
- Dividend yield
- 1.20%
Piramal Pharma compared with sector peers on revenue, market capitalization, valuation, and return metrics.
Piramal Pharma sector benchmarking & peer comparison
Operational and financial KPI comparison against sector peers.
| Company | LTP (₹) | P/E | Market Cap (₹ cr) | Div Yield | Qtr Sales (₹ cr) | ROCE % |
|---|---|---|---|---|---|---|
| Piramal Pharma Limited | ₹202.63 | 22.5 | 26,843 | 1.2% | 4,500 | -4.0% |
| Median (1 Cos) | ₹202.63 | 22.5 | 26,843 | 1.2% | 4,500 | -4.0% |
Source: NSE sector index filings and financial statements. Data as of 7 October 2026. How this data is compiled.
Same Data For Peers
- Sun Pharmaceutical Industries Limited operational benchmarking
- Divi's Laboratories Limited operational benchmarking
- Torrent Pharmaceuticals Limited operational benchmarking
- Zydus Lifesciences Limited operational benchmarking
- Laurus Labs Limited operational benchmarking
- Cipla Limited operational benchmarking
Trade Piramal Pharma With ATS
Track PPLPHARMA live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.